Literature DB >> 12466468

The formation and function of extracellular enveloped vaccinia virus.

Geoffrey L Smith1, Alain Vanderplasschen1, Mansun Law1.   

Abstract

Vaccinia virus produces four different types of virion from each infected cell called intracellular mature virus (IMV), intracellular enveloped virus (IEV), cell-associated enveloped virus (CEV) and extracellular enveloped virus (EEV). These virions have different abundance, structure, location and roles in the virus life-cycle. Here, the formation and function of these virions are considered with emphasis on the EEV form and its precursors, IEV and CEV. IMV is the most abundant form of virus and is retained in cells until lysis; it is a robust, stable virion and is well suited to transmit infection between hosts. IEV is formed by wrapping of IMV with intracellular membranes, and is an intermediate between IMV and CEV/EEV that enables efficient virus dissemination to the cell surface on microtubules. CEV induces the formation of actin tails that drive CEV particles away from the cell and is important for cell-to-cell spread. Lastly, EEV mediates the long-range dissemination of virus in cell culture and, probably, in vivo. Seven virus-encoded proteins have been identified that are components of IEV, and five of them are present in CEV or EEV. The roles of these proteins in virus morphogenesis and dissemination, and as targets for neutralizing antibody are reviewed. The production of several different virus particles in the VV replication cycle represents a coordinated strategy to exploit cell biology to promote virus spread and to aid virus evasion of antibody and complement.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466468     DOI: 10.1099/0022-1317-83-12-2915

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  237 in total

1.  Intracellular trafficking of a palmitoylated membrane-associated protein component of enveloped vaccinia virus.

Authors:  Matloob Husain; Bernard Moss
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

2.  Investigation of structural and functional motifs within the vaccinia virus A14 phosphoprotein, an essential component of the virion membrane.

Authors:  Jason Mercer; Paula Traktman
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

3.  Increased interaction between vaccinia virus proteins A33 and B5 is detrimental to infectious extracellular enveloped virion production.

Authors:  Winnie M Chan; Brian M Ward
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

4.  The A33-dependent incorporation of B5 into extracellular enveloped vaccinia virions is mediated through an interaction between their lumenal domains.

Authors:  Winnie M Chan; Brian M Ward
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

5.  There is an A33-dependent mechanism for the incorporation of B5-GFP into vaccinia virus extracellular enveloped virions.

Authors:  Winnie M Chan; Brian M Ward
Journal:  Virology       Date:  2010-04-07       Impact factor: 3.616

6.  Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.

Authors:  Douglas W Grosenbach; Robert Jordan; Dennis E Hruby
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

7.  Characterization of ectromelia virus deficient in EVM036, the homolog of vaccinia virus F13L, and its application for rapid generation of recombinant viruses.

Authors:  Felicia Roscoe; Ren-Huan Xu; Luis J Sigal
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

8.  Antibody responses to vaccinia membrane proteins after smallpox vaccination.

Authors:  Steven J Lawrence; Kathleen R Lottenbach; Frances K Newman; R Mark L Buller; Clifford J Bellone; John J Chen; Gary H Cohen; Roselyn J Eisenberg; Robert B Belshe; Samuel L Stanley; Sharon E Frey
Journal:  J Infect Dis       Date:  2007-06-04       Impact factor: 5.226

9.  Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells.

Authors:  Juan Carlos Gallego-Gómez; Cristina Risco; Dolores Rodríguez; Pilar Cabezas; Susana Guerra; José L Carrascosa; Mariano Esteban
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Characterization of murine antibody responses to vaccinia virus envelope protein A14 reveals an immunodominant antigen lacking of effective neutralization targets.

Authors:  Xiangzhi Meng; Thomas Kaever; Bo Yan; Paula Traktman; Dirk M Zajonc; Bjoern Peters; Shane Crotty; Yan Xiang
Journal:  Virology       Date:  2018-03-17       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.